


FILED

Exhibit 3

2007 JAN 23 AM 10:20

RICHARD J. ROSENTHAL

Multi-State Attorney General Consent Judgment with Bayer Corporation

 D.C.

PUBLIC ACCESS TO SUMMARIES OF BAYER CLINICAL
STUDIES ON CLINICALSTUDYRESULTS.ORG

Bayer Corporation announced that Bayer will post on ClinicalStudyResults.org summaries of the clinical study reports for all Phase II, III and IV Bayer-sponsored clinical studies conducted on Bayer's drugs.

Access to this information is unrestricted and free-of-charge. The content of the summaries will conform to the principles required by the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Guidelines for Industry: Structure and Content of Clinical Study Reports (ICH's E-3 Guidance). The content of the summaries will also conform to the template published in the Federal Register, Vol. 61, July 17, 1996, Page 37320 *et seq.*

Bayer will make all reasonable efforts to post within the next four months, the summaries of clinical study reports that were completed since July 1, 2005. Bayer shall, in general, post the summaries of clinical studies that are completed in the future within 12 months of the study completion date or upon first marketing. In some cases, the timing may be affected by the policies of a peer reviewed journal that has accepted an article about the study.

There may be a delay in posting complete summaries of clinical study reports because Bayer may seek intellectual-property protection or comply with policies of peer-reviewed journals to which manuscripts have been submitted for publication. Further, Bayer may be required to withhold certain summaries of clinical study reports to comply with confidentiality provisions in agreements with other parties. In regard to confidentiality agreements, in all future clinical studies, Bayer will use reasonable efforts to exclude provisions limiting the publication of summaries of clinical study reports. For all past clinical studies with such confidentiality agreements, Bayer will make reasonable efforts to secure the right to post the summaries of clinical study reports.

Questions concerning Bayer's registry should be directed to: Bayer Clinical Communications at 800-288-8371.